Al
Non verificato

Alkermes plc

Di cosa scriviamo

BiologiaComunicazioneFarmaceuticaMediaSanità
25/02/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Sanità
Psichiatria
Salute
Farmaceutica
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
1.00
25/02/2026
Mercato del lavoro
Biotecnologia
Psichiatria
Salute
Farmaceutica
Alkermes plc Announces CEO Succession Plan
1.00
24/02/2026
Eventi
Web e Social Network
Biotecnologia
Sanità
Psichiatria
Salute
Farmaceutica
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
1.00
12/02/2026
Mercato azionario
Industria
Biotecnologia
Sanità
Psichiatria
Salute
Farmaceutica
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
1.00
11/02/2026
Biotecnologia
Sanità
Psichiatria
Salute
Farmaceutica
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
1.00
06/01/2026
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Psichiatria
Medicina - Varie
Industria
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
1.00
30/12/2026
Biotecnologia
Farmaceutica
Salute
Psichiatria
Web e Social Network
Eventi
Finanza
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
1.00
25/11/2025
Eventi
Web e Social Network
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Alkermes to Participate in Two Upcoming Investor Conferences
1.00
Press Release cover image
29/07/2025
Salute
Fitness
Economia
Medicina - Varie
Alkermes plc Reports Second Quarter 2025 Financial Results
1.00
Press Release cover image
21/07/2025
Salute
Fitness
Medicina - Varie
Ecologia/Salute ambientale
Agricoltura
Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0